Patents Examined by Raymond J. Henley, III
  • Patent number: 11317646
    Abstract: Disclosed are methods and compositions of reducing the epigenetic age of mammalian organism, especially an adult human of geriatric age. The methods provide for the proliferation of endogenous stem cells using mitochondrial fusion and a UCP2 blocker or other stimulants; supplying stem cells with nutrition to prevent cell cycle arrest; and removal of senescent somatic cells using senolytic treatments. The proliferation of endogenous neural stem cells after plaque removal for the treatment of Alzheimer's is also disclosed.
    Type: Grant
    Filed: August 14, 2019
    Date of Patent: May 3, 2022
    Inventor: Louis Dischler
  • Patent number: 11318118
    Abstract: This invention provides compositions and methods for treatment of mild, moderate and severe stages of SARS-CoV-2 infection, particularly COVID-19 disease caused by wild type and mutant strains of SARS-CoV-2 using 5-amino-1-(4-(4-chlorobenzyl)-1, 2, 3-triazole-4-carboxamide orotate. Carboxyamidotriazole orotate (CTO) alone or in combination with other therapeutics in standard of clinical care are useful for directing antiviral effects and host-directed antiviral effects against wild type and mutant strains of SARS-CoV-2 throughout the viral life cycle.
    Type: Grant
    Filed: April 5, 2021
    Date of Patent: May 3, 2022
    Assignee: TACTICAL THERAPEUTICS INC.
    Inventor: Rashida A. Karmali
  • Patent number: 11311522
    Abstract: This invention relates to methods and materials for treating mammals having, or at risk of developing, one or more movement disorders (e.g., essential tremor, epilepsy, and/or Parkinson's disease). For example, compositions including one or more T-type calcium channel antagonists (e.g., one or more Cav3 antagonists such as CX-8998) are provided, as well as methods for administering such compositions to a mammal having, or at risk of developing, one or more movement disorders (e.g., essential tremor, epilepsy, and/or Parkinson's disease) to treat the mammal.
    Type: Grant
    Filed: May 6, 2021
    Date of Patent: April 26, 2022
    Assignee: CAVION, INC.
    Inventors: Margaret S. Lee, Spyridon Papapetropoulos, Michelle S. Higgin, Muralikrishna Duvvuri, Bruce N. Rehlaender, Evan Newbold
  • Patent number: 11311538
    Abstract: In various aspects and embodiments the invention provides a method of treating or preventing a cancer in a mammalian subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of at least one compound selected from the group consisting of a DNA repair inhibitor, a DNA strand break repair inhibitor, and a homologous recombination (HR) repair inhibitor, wherein cells in the cancer comprise a fumarate hydratase (FH) and/or succinate dehydrogenase (SDH) mutation.
    Type: Grant
    Filed: July 12, 2019
    Date of Patent: April 26, 2022
    Assignee: YALE UNIVERSITY
    Inventors: Ranjit Bindra, Peter Glazer, Parker Sulkowski, Brian Shuch
  • Patent number: 11311524
    Abstract: The present invention provides a pharmaceutical composition containing an inhibitor selected from the group consisting of an EZH1 inhibitor, an EZH2 inhibitor and an EZH1/2 dual inhibitor as an active ingredient, for use in treating HTLV-1-associated myelopathy. The present invention provides a pharmaceutical composition for use in treating HTLV-1-associated myelopathy, containing a 1,3-benzodioxole derivative or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: January 18, 2018
    Date of Patent: April 26, 2022
    Assignees: DAIICHI SANKYO COMPANY, LIMITED, ST. MARIANNA UNIVERSITY SCHOOL OF MEDICINE
    Inventors: Yoshihisa Yamano, Natsumi Ueda, Kazushi Araki
  • Patent number: 11304940
    Abstract: Provided are methods for treatment of Fabry disease in patients having HEK assay amenable mutations in ?-galactosidase A. Certain methods comprise administering migalastat or a salt thereof every other day, such as administering about 150 mg of migalastat hydrochloride every other day.
    Type: Grant
    Filed: August 4, 2021
    Date of Patent: April 19, 2022
    Assignee: Amicus Therapeutics, Inc.
    Inventors: Jeff Castelli, Elfrida Benjamin
  • Patent number: 11298343
    Abstract: Methods for removing excess free ?-globin in erythroid cells and treating a thalassemia using an agent that activates Unc-51 Like autophagy activating Kinase (ULK) are described.
    Type: Grant
    Filed: October 26, 2018
    Date of Patent: April 12, 2022
    Assignee: ST. JUDE CHILDREN'S RESEARCH HOSPITAL
    Inventors: Mitchell J. Weiss, Mondira Kundu, Christophe Lechauve
  • Patent number: 11291666
    Abstract: The disclosure provides the administration of inhibitors of phosphodiesterase 1 (PDE1) for the treatment and prophylaxis of diseases or disorders characterized by inflammation, e.g., neuroinflammation, including methods of treatment and pharmaceutical compositions for use therein.
    Type: Grant
    Filed: September 12, 2017
    Date of Patent: April 5, 2022
    Assignee: INTRA-CELLULAR THERAPIES, INC.
    Inventors: Gretchen Snyder, Lawrence P. Wennogle, Jennifer O'Brien, Joseph Hendrick
  • Patent number: 11285215
    Abstract: Disclosed herein are compositions comprising an NSAID such as meloxicam and/or rizatriptan in combination with a cyclodextrin and/or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a Tmax of meloxicam of 3 hours or less.
    Type: Grant
    Filed: May 20, 2021
    Date of Patent: March 29, 2022
    Assignee: AXSOME THERAPEUTICS, INC.
    Inventor: Herriot Tabuteau
  • Patent number: 11285149
    Abstract: The present invention relates to a combination of a signal transducer and activator of transcription 3 (STAT3) activity inhibitor; and an immune checkpoint inhibitor for use in treating or preventing the hyperproliferative disorder in a subject. Preferably, the STA3 activity inhibitor is pyrimethamine or atovaquone, and the immune checkpoint inhibitor is an anti-PD1 antibody. Preferably, the hyperproliferative disorder is a glioma or a glioblastoma.
    Type: Grant
    Filed: July 27, 2018
    Date of Patent: March 29, 2022
    Assignee: DANA-FARBER CANCER INSTITUTE, INC.
    Inventors: David Frank, Darwin Ye
  • Patent number: 11278540
    Abstract: Provided are methods for treatment of Fabry disease in patients having HEK assay amenable mutations in ?-galactosidase A. Certain methods comprise administering migalastat or a salt thereof every other day, such as administering about 150 mg of migalastat hydrochloride every other day.
    Type: Grant
    Filed: August 13, 2021
    Date of Patent: March 22, 2022
    Assignee: Amicus Therapeutics, Inc.
    Inventors: Jeff Castelli, Elfrida Benjamin
  • Patent number: 11278537
    Abstract: Provided are methods for treatment of Fabry disease in patients having HEK assay amenable mutations in ?-galactosidase A. Certain methods comprise administering migalastat or a salt thereof every other day, such as administering about 150 mg of migalastat hydrochloride every other day.
    Type: Grant
    Filed: August 12, 2021
    Date of Patent: March 22, 2022
    Assignee: Amicus Therapeutics, Inc.
    Inventors: Jeff Castelli, Elfrida Benjamin
  • Patent number: 11278538
    Abstract: Provided are methods for treatment of Fabry disease in patients having HEK assay amenable mutations in ?-galactosidase A. Certain methods comprise administering migalastat or a salt thereof every other day, such as administering about 150 mg of migalastat hydrochloride every other day.
    Type: Grant
    Filed: August 12, 2021
    Date of Patent: March 22, 2022
    Assignee: Amicus Therapeutics, Inc.
    Inventors: Jeff Castelli, Elfrida Benjamin
  • Patent number: 11278539
    Abstract: Provided are methods for treatment of Fabry disease in patients having HEK assay amenable mutations in ?-galactosidase A. Certain methods comprise administering migalastat or a salt thereof every other day, such as administering about 150 mg of migalastat hydrochloride every other day.
    Type: Grant
    Filed: August 12, 2021
    Date of Patent: March 22, 2022
    Assignee: Amicus Therapeutics, Inc.
    Inventors: Jeff Castelli, Elfrida Benjamin
  • Patent number: 11278536
    Abstract: Provided are methods for treatment of Fabry disease in patients having HEK assay amenable mutations in ?-galactosidase A. Certain methods comprise administering migalastat or a salt thereof every other day, such as administering about 150 mg of migalastat hydrochloride every other day.
    Type: Grant
    Filed: August 12, 2021
    Date of Patent: March 22, 2022
    Assignee: Amicus Therapeutics, Inc.
    Inventors: Jeff Castelli, Elfrida Benjamin
  • Patent number: 11273152
    Abstract: This invention relates to the finding that Piperlongumine compounds, such as Piperlongumine and analogues, derivatives and prodrugs thereof, are reversible, allosteric antagonists of transient receptor potential vanilloid 2 channel (TRPV2). Methods of treatment of conditions that are characterised by TRPV2 expression using Piperlongumine compounds and Piperlongumine compounds for use in such treatments are provided.
    Type: Grant
    Filed: September 14, 2018
    Date of Patent: March 15, 2022
    Assignee: Instituto de Medicina Molecular João Lobo Antunes
    Inventors: Goncalo Bernardes, Tiago Rodrigues, João Conde, Charlotte Baker
  • Patent number: 11266661
    Abstract: Disclosed herein is, among other things, a soft gel vaginal pharmaceutical composition and dosage form containing solubilized estradiol for the treatment of vulvovaginal atrophy (VVA) and female sexual dysfunction (FSD).
    Type: Grant
    Filed: December 7, 2016
    Date of Patent: March 8, 2022
    Assignee: TherapeuticsMD, Inc.
    Inventors: Sebastian Mirkin, Julia M. Amadio, Brian Bernick
  • Patent number: 11266641
    Abstract: Described herein are formulations of a somatostatin modulator, methods of making such formulations, and methods of using such formulations in the treatment of conditions, diseases, or disorders that would benefit from modulation of somatostatin activity.
    Type: Grant
    Filed: September 7, 2021
    Date of Patent: March 8, 2022
    Assignee: CRINETICS PHARMACEUTICALS, INC.
    Inventors: Gerald Burke, Ian Yates, Hannah Bulovsky, Kyle Kyburz, Clayton Tyler
  • Patent number: 11266615
    Abstract: Pharmaceutical compositions that include aqueous suspensions of therapeutically effective quantity of a diaminopyrimidine compound (such as pyrimethamine) are provided herein. Methods for fabricating and using the compositions, and kits that include the compositions are also described.
    Type: Grant
    Filed: April 20, 2020
    Date of Patent: March 8, 2022
    Inventor: Dennis Elias Saadeh
  • Patent number: 11260042
    Abstract: A pharmaceutical combination comprising (A): a polyunsaturated fatty acid and (B): a chemotherapeutic agent compound for the simultaneous, separate or sequential use in the treatment of a cancer in a human patient.
    Type: Grant
    Filed: May 15, 2018
    Date of Patent: March 1, 2022
    Assignee: ABILITY PHARMACEUTICALS S.L.
    Inventors: Carles Domènech Garcia, José Alberto Alfón Coriat, Héctor Pérez Montoyo, Miguel Francisco Segura Ginard, Jose Miguel Lizcano De Vega